Axial Therapeutics Announces Completion of Enrollment in Global Phase 2b Clinical Trial for AB-2004 for Irritability Associated with Autism
September 26, 2023 08:00 ET
|
Axial Therapeutics
– Topline clinical data anticipated in 1Q 2024 – – First-in-class small molecule therapeutic targets the microbiome gut-brain axis and its role in autism, offering a potential alternative to...
Autism Spectrum Disorder Therapeutics Market Size to Surpass USD 3.42 Billion by 2030, exhibiting a CAGR of 7.9%
August 31, 2023 07:24 ET
|
Fortune Business Insights
Pune, India, Aug. 31, 2023 (GLOBE NEWSWIRE) -- The global autism spectrum disorder therapeutics market size was valued at USD 1.93 billion in 2022 and it is projected to grow from USD 2.01 billion...
DisruptABA™ Virtual Conference: Pursuing Radical Honesty and Change in Applied Behavior Analysis
August 02, 2023 09:00 ET
|
Verbal Beginnings
COLUMBIA, Md., Aug. 02, 2023 (GLOBE NEWSWIRE) -- The Applied Behavior Analysis (ABA) professional community is eagerly anticipating the groundbreaking virtual conference, DisruptABA™, which is set...
PharmAla Files Patent for Novel MDXX Molecule PharmAla-1
July 31, 2023 08:30 ET
|
PharmAla Biotech
VANCOUVER, British Columbia, July 31, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research,...
PharmAla Received Guidance on ALA-002 from MHRA; Launches Clinical Program with University of Sydney
July 20, 2023 09:07 ET
|
PharmAla Biotech
VANCOUVER, British Columbia, July 20, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research,...
PaxMedica Grants Exclusive Pharmacy Distribution Rights for PAX-101 to Vox Nova, LLC
July 06, 2023 08:00 ET
|
PaxMedica, Inc.
· Agreement for PAX-101 (suramin IV) Distribution in the U.S. for up to 7 years · VoxNova will be responsible for physician registration, safety monitoring and reimbursement for treatment, as...
Autism Spectrum Disorder Treatment Market Size to Surpass USD 3.42 billion by 2030, exhibiting a CAGR of 7.9%
June 21, 2023 04:50 ET
|
Fortune Business Insights
Pune, India, June 21, 2023 (GLOBE NEWSWIRE) -- According to Fortune Business Insights, global Autism Spectrum Disorder Treatment Market size was valued at USD 1.93 billion in 2022 and is projected...
CAI Neurodiverse Solutions and Drexel University Create Job Opportunities for Philadelphia-area Neurodivergent Graduates
May 17, 2023 09:00 ET
|
CAI
ALLENTOWN, Pa., May 17, 2023 (GLOBE NEWSWIRE) -- CAI, a global technology services firm, and Drexel University’s Center for Autism and Neurodiversity (CAN), a student-centered program that provides...
Little Leaves Behavioral Services Appoints Dr. Ivy Chong Chief Clinical Officer
May 16, 2023 08:40 ET
|
Little Leaves
SILVER SPRING, Md., May 16, 2023 (GLOBE NEWSWIRE) -- Little Leaves Behavioral Services, a leading provider of center-based behavioral health services and early intervention for preschool-aged...
Axial Therapeutics Announces Age Expansion in Global Phase 2b Clinical Trial for Irritability Associated with Autism Spectrum Disorder (ASD)
April 04, 2023 08:00 ET
|
Axial Therapeutics
-- Children aged 5 to 17 with autism are now eligible to enroll in the clinical trial of AB-2004, a gut targeted, molecular therapeutic -- -- Novel small molecule microbiome approach focused on...